Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $50.00 | $5.00/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| RP052226 | — | 99.4% | Kovera Labs | Endotoxin, Sterility, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHRP-2 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Real Peptides sell GHRP-2?
Yes — Real Peptides currently lists GHRP-2 in 1 variant starting at $50.00 ($5.00/mg).
Is Real Peptides's GHRP-2 third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Real Peptides's GHRP-2, with the most recent showing 99.4% purity. Real Peptides holds an overall trust grade of B (83/100) across all 142 COAs on file.
What is Real Peptides's trust grade for GHRP-2?
Real Peptides has an overall Disclosed Labs trust grade of B (83/100), computed from 142 COAs across all peptides. The most recent GHRP-2 COA was issued by Kovera Labs.
Where is the cheapest GHRP-2?
As of the latest data, Verified Peptides offers GHRP-2 at $1.62/mg — compare with Real Peptides's listing at $5.00/mg. See the full GHRP-2 price comparison.
Is GHRP-2 legal to buy?
GHRP-2 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| BATCH-0322 | — | 98.8% | Kovera Labs | Endotoxin, Heavy metals | Unverified | View |
Disclosed Labs